<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090895</url>
  </required_header>
  <id_info>
    <org_study_id>Violi012009</org_study_id>
    <nct_id>NCT01090895</nct_id>
  </id_info>
  <brief_title>Treatment of Reperfusion Event by Vitamin C Infusion</brief_title>
  <acronym>TREVI</acronym>
  <official_title>Effect of Vitamin C Infusion on Coronary Reperfusion Indexes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Hypothesis: Prophylactic Vitamin C Intravenous Infusion at the time of percutaneous
      coronary intervention (PCI) would limit the size of the infarct, assessed by measurements of
      cardiac biomarkers, during acute myocardial infarction.

      Secondary Hypotheses: Prophylactic Vitamin C Intravenous Infusion at the time of percutaneous
      coronary intervention (PCI) would limit the size of the infarct, as measured by the area of
      delayed hyperenhancement that was seen on cardiac magnetic resonance imaging (MRI), assessed
      on day 5 after infarction, during acute myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, controlled, randomized study that will be conducted at up
      to 5 centers in Italy. All patients who meet the eligibility criteria will be randomized to
      receive during surgical procedure an intravenous infusion of Vitamin C or Placebo.

      Patients will have repeat clinical follow-up to 5 days, 3 and 6 months and 1 year.

      The new angiography evaluation will be done if necessary. The study population will consist
      of at least 100 patients who presented within 12 hours after the onset of chest pain, who had
      ST-segment elevation of more than 0.1 mV in two contiguous leads, and for whom the clinical
      decision was made to treat with percutaneous coronary intervention (PCI). Following
      confirmation of eligibility criteria, patients will be randomized in a 1:1 ratio to receive
      prophylactic infusion of Vitamin C or Placebo. The coronary angiograms will be assessed at a
      core laboratory with Quantitative Coronary Angiography.

      The incidence of clinical events, including death, myocardial infarction, target vessel
      revascularization, stent thrombosis, will be evaluated at 1, 3, 6 and, 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific key observations used to measure the effect of experimental treatment in this study are the incidence of Major Adverse Cardiovascular Events.</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular Death, Myocardial Infarction, Stent Thrombosis, Repeat Revascularization, Stroke, Transient Ischemic Attack</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial damage and microcoronary disfunction by cardiac magnetic resonance imaging</measure>
    <time_frame>7 days</time_frame>
    <description>Prophylactic Vitamin C Intravenous Infusion at the time of percutaneous coronary intervention (PCI) would limit the size of damage within 7 days after PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of reperfusion indexes (corrected Thrombolysis In Myocardial Infarction frame count and myocardial blush grade)</measure>
    <time_frame>post PCI</time_frame>
    <description>Prophylactic Vitamin C Intravenous Infusion at the time of percutaneous coronary intervention (PCI) could improve the reperfusion indexes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early incidence of Major Adverse Cardiovascular Events.</measure>
    <time_frame>1 month</time_frame>
    <description>Cardiovascular Death, Myocardial Infarction, Stent Thrombosis, Repeat Revascularization, Stroke, Transient Ischemic Attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late incidence of Major Adverse Cardiovascular Events.</measure>
    <time_frame>3 months</time_frame>
    <description>Cardiovascular Death, Myocardial Infarction, Stent Thrombosis, Repeat Revascularization, Stroke, Transient Ischemic Attack</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin C infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.</description>
    <arm_group_label>Vitamin C</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who presented within 12 hours after the onset of chest pain, who had
             ST-segment elevation of more than 0.1 mV in two contiguous leads, and for whom the
             clinical decision was made to treat with percutaneous coronary intervention (PCI)

          -  Patients will be eligible for the study whether they were undergoing primary PCI.

          -  Signed written informed consent

        Exclusion Criteria:

          -  Patients with cardiac arrest, ventricular fibrillation, cardiogenic shock, stent
             thrombosis, previous acute myocardial infarction, or angina within 48 hours before
             infarction were not included in the study

          -  Patients with evidence of coronary collaterals (2-3 Rentrop) to the region at risk on
             initial coronary angiography (at the time of admission) will be excluded

          -  The patient has impaired renal function (creatinine &gt; 3.0 mg/dl)

          -  The patient has known allergies to aspirin, clopidogrel bisulfate and ticlopidine,
             heparin, contrast media or stainless steel that cannot be managed medically

          -  The patient needs therapy with warfarin

          -  The patient has a life expectancy less than 12 months

          -  Recipient of heart transplant

          -  The patient is currently participating in an investigational drug or another device
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Violi, Full Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Divisione di Prima Clinica Medica - Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Violi, Full Prof</last_name>
    <phone>+39-06-4461933</phone>
    <email>francesco.violi@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefania Basili, Ass Prof</last_name>
    <phone>+39-06-49974678</phone>
    <email>stefania.basili@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sapienza Universit√† di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Violi, Full Prof</last_name>
      <phone>+39-06-4461933</phone>
      <email>francesco.violi@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefania Basili, Ass Prof</last_name>
      <phone>+39-06-49974678</phone>
      <email>stefania.basili@uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Tanzilli Gaetano, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mangieri Enrico, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raparelli Valeria, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pignatelli P, Sanguigni V, Paola SG, Lo Coco E, Lenti L, Violi F. Vitamin C inhibits platelet expression of CD40 ligand. Free Radic Biol Med. 2005 Jun 15;38(12):1662-6. Epub 2005 Mar 23.</citation>
    <PMID>15917194</PMID>
  </reference>
  <reference>
    <citation>Cordova C, Musca A, Violi F, Perrone A, Alessandri C. Influence of ascorbic acid on platelet aggregation in vitro and in vivo. Atherosclerosis. 1982 Jan;41(1):15-9.</citation>
    <PMID>7073791</PMID>
  </reference>
  <reference>
    <citation>Basili S, Tanzilli G, Mangieri E, Raparelli V, Di Santo S, Pignatelli P, Violi F. Intravenous ascorbic acid infusion improves myocardial perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers. JACC Cardiovasc Interv. 2010 Feb;3(2):221-9. doi: 10.1016/j.jcin.2009.10.025.</citation>
    <PMID>20170881</PMID>
  </reference>
  <reference>
    <citation>Violi F, Cangemi R. Antioxidant supplements and cardiovascular disease in men. JAMA. 2009 Apr 1;301(13):1335; author reply 1336-7. doi: 10.1001/jama.2009.314.</citation>
    <PMID>19336704</PMID>
  </reference>
  <reference>
    <citation>Cangemi R, Angelico F, Loffredo L, Del Ben M, Pignatelli P, Martini A, Violi F. Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radic Biol Med. 2007 Sep 1;43(5):853-9. Epub 2007 Jun 13.</citation>
    <PMID>17664149</PMID>
  </reference>
  <reference>
    <citation>Basili S, Pignatelli P, Tanzilli G, Mangieri E, Carnevale R, Nocella C, Di Santo S, Pastori D, Ferroni P, Violi F. Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1766-71. doi: 10.1161/ATVBAHA.111.227959. Epub 2011 Jun 2.</citation>
    <PMID>21636808</PMID>
  </reference>
  <reference>
    <citation>Basili S, Tanzilli G, Raparelli V, Calvieri C, Pignatelli P, Carnevale R, Dominici M, Placanica A, Arrivi A, Farcomeni A, Barill√† F, Mangieri E, Violi F. Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. Circ Cardiovasc Interv. 2014 Aug;7(4):577-84. doi: 10.1161/CIRCINTERVENTIONS.113.001197. Epub 2014 Jul 29.</citation>
    <PMID>25074252</PMID>
  </reference>
  <results_reference>
    <citation>Pignatelli P, Tanzilli G, Carnevale R, Di Santo S, Loffredo L, Celestini A, Proietti M, Tovaglia P, Mangieri E, Basili S, Violi F. Ascorbic acid infusion blunts CD40L upregulation in patients undergoing coronary stent. Cardiovasc Ther. 2011 Dec;29(6):385-94. doi: 10.1111/j.1755-5922.2010.00168.x. Epub 2010 Jul 12.</citation>
    <PMID>20629665</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2010</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Violi</investigator_full_name>
    <investigator_title>Full professor of internal medicine</investigator_title>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Magnetic Risonance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

